Longeveron Announces $30 Million Private Placement Financing

Longeveron ( (LGVN) ) has issued an update.

On March 10, 2026, Longeveron entered into a securities purchase agreement for a private placement of up to approximately $30 million, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare funds, priced at-the-market under Nasdaq rules. The initial closing on March 11, 2026, raised about $15 million through the sale of 6,013,384 Class A common shares at $0.52 and 11,873.04 Series A non-voting convertible preferred shares, immediately convertible at the same price into 22,832,770 common shares, alongside an investor right to 50% of potential net proceeds from any future sale of an FDA Rare Pediatric Disease Priority Review Voucher tied to the laromestrocel HLHS program.

Concurrently, Longeveron filed a Certificate of Designation in Delaware authorizing up to 26,975 Series A preferred shares, which carry no general voting or liquidation preference but receive dividends on an as-converted basis and grant holders protective voting rights over key corporate actions and further preferred issuance. The financing is expected to extend the company’s cash runway into the fourth quarter of 2026, past the anticipated third-quarter 2026 topline readout of the pivotal Phase 2b ELPIS II trial in HLHS, positioning Longeveron to advance its laromestrocel pipeline while introducing potential dilution and a future revenue-sharing component linked to any priority review voucher sale for stakeholders to consider.

The most recent analyst rating on (LGVN) stock is a Hold with a $0.53 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Spark’s Take on LGVN Stock

According to Spark, TipRanks’ AI Analyst, LGVN is a Underperform.

Longeveron’s overall stock score is heavily impacted by its poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. While there are some positive developments in clinical trials and corporate governance, these are overshadowed by financial instability and the risk of Nasdaq delisting.

To see Spark’s full report on LGVN stock, click here.

More about Longeveron

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative cell-based medicines for life-threatening rare pediatric and chronic aging-related conditions. Its lead investigational product, laromestrocel (LOMECEL-B), an allogeneic mesenchymal stem cell therapy from young adult bone marrow donors, is being advanced for hypoplastic left heart syndrome, Alzheimer’s disease and pediatric dilated cardiomyopathy, supported by multiple FDA designations across these programs.

Average Trading Volume: 4,672,068

Technical Sentiment Signal: Sell

Current Market Cap: $17.33M

For an in-depth examination of LGVN stock, go to TipRanks’ Overview page.